

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1 to 4 (canceled).

Claim 5 (currently amended). A method for inhibiting a viral infection in a mammalian cell, comprising contacting the cell with an effective amount of an imidazoquinoline compound or poly I:C to stimulate induction of interferon regulatory factor 3-IRF3 in the mammalian cell, thereby increasing expression of interferon β in the cell and inhibiting the viral infection.

Claims 6 to 19 (canceled).

Claim 20 (currently amended). A method for inhibiting viral replication in a cell by stimulating the induction of TLR3/TLR4 and interferon regulatory factor 3-IRF3 pathways in the cell, comprising contacting the cell with an effective amount of an imidazoquinoline compound poly I:C, thereby increasing expression of interferon β in the cell and inhibiting the viral replication in the cell.

Claims 21 to 24 (canceled).

Claim 25 (previously presented). The method of claim 5, wherein the cell is a macrophage.

Claim 26 (previously presented). The method of claim 20, wherein the cell is a macrophage.

Claim 27 (new). The method of claim 5, wherein said inhibiting is *in vivo*.

Claim 28 (new). The method of claim 5, wherein said inhibiting is *in vitro*.

Claim 29 (new). The method of claim 20, wherein said inhibiting is *in vivo*.

Claim 30 (new). The method of claim 20, wherein said inhibiting is *in vitro*.

Claim 31 (new). A method of inhibiting a viral infection in a human, comprising administering to the human an effective amount of poly I:C to stimulate induction of interferon regulatory factor 3 and increase the expression of interferon β , thereby inhibiting the viral infection.